Literature DB >> 23648131

Next-generation sequencing study finds an excess of rare, coding single-nucleotide variants of ADAMTS13 in patients with deep vein thrombosis.

L A Lotta1, G Tuana, J Yu, I Martinelli, M Wang, F Yu, S M Passamonti, E Pappalardo, C Valsecchi, S E Scherer, W Hale, D M Muzny, G Randi, F R Rosendaal, R A Gibbs, F Peyvandi.   

Abstract

BACKGROUND: The considerable genetic predisposition to deep vein thrombosis (DVT) is only partially accounted for by known genetic risk variants. Rare single-nucleotide variants (SNVs) of the coding areas of hemostatic genes may explain part of this missing heritability. The ADAMTS13 and VWF genes encode two interconnected proteins with fundamental hemostatic functions, the disruption of which may result in thrombosis.
OBJECTIVES: To study the distribution and burden of rare coding SNVs of ADAMTS13 and VWF found by sequencing in cases and controls of DVT. PATIENTS/
METHODS: The protein-coding areas of 186 hemostatic/proinflammatory genes were sequenced by next-generation technology in 94 thrombophilia-negative patients with DVT and 98 controls. Gene-specific information on ADAMTS13 and VWF was used to study the association between DVT and rare coding SNVs of the two genes.
RESULTS: More than 70 billion base pairs of raw sequence data were produced to sequence the 700-kb target area with a median redundancy of × 45 in 192 individuals. Most of the 4366 SNVs identified were rare and non-synonymous, indicating pathogenetic potential. Rare (frequency of < 1%) and low-frequency (< 5%) coding SNVs of ADAMTS13 were associated with DVT (prevalence 17% vs. 4%; odds ratio [OR] 4.8 and 95% confidence interval [CI] 1.6-15.0 for rare coding; prevalence 36% vs. 23%, OR 1.9 and 95% CI 1.0-3.5 for low-frequency coding). Patients with rare coding SNVs of ADAMTS13 had lower plasma levels of ADAMTS-13 activity than patients without them. SNVs of VWF were not associated with DVT.
CONCLUSIONS: We found an excess of rare coding SNVs of the ADAMTS13 gene in patients with DVT.
© 2013 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  ADAMTS-13; VWF; deep vein thrombosis; exome; venous thromboembolism

Mesh:

Substances:

Year:  2013        PMID: 23648131     DOI: 10.1111/jth.12291

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  12 in total

1.  Whole-exome sequencing in evaluation of patients with venous thromboembolism.

Authors:  Eun-Ju Lee; Daniel J Dykas; Andrew D Leavitt; Rodney M Camire; Eduard Ebberink; Pablo García de Frutos; Kavitha Gnanasambandan; Sean X Gu; James A Huntington; Steven R Lentz; Koen Mertens; Christopher R Parish; Alireza R Rezaie; Peter P Sayeski; Caroline Cromwell; Noffar Bar; Stephanie Halene; Natalia Neparidze; Terri L Parker; Adrienne J Burns; Anne Dumont; Xiaopan Yao; Cassius Iyad Ochoa Chaar; Jean M Connors; Allen E Bale; Alfred Ian Lee
Journal:  Blood Adv       Date:  2017-06-29

Review 2.  von Willebrand factor, Jedi knight of the bloodstream.

Authors:  Timothy A Springer
Journal:  Blood       Date:  2014-06-13       Impact factor: 22.113

3.  Identification of mutations in SLC4A1, GP1BA and HFE in a family with venous thrombosis of unknown cause by next-generation sequencing.

Authors:  Wei-An Chang; Chau-Chyun Sheu; Kuan-Ting Liu; Jheng-Heng Shen; Meng-Chi Yen; Po-Lin Kuo
Journal:  Exp Ther Med       Date:  2018-09-04       Impact factor: 2.447

4.  ADAMTS13 missense variants associated with defective activity and secretion of ADAMTS13 in a patient with non-cirrhotic portal hypertension.

Authors:  Ashish Goel; V Raghupathy; G J Amirtharaj; Aaron Chapla; Aparna Venkatraman; Banumathi Ramakrishna; Anup Ramachandran; Nihal Thomas; K A Balasubramanian; Ian Mackie; Elwyn Elias; Chundamannil E Eapen
Journal:  Indian J Gastroenterol       Date:  2017-10-05

Review 5.  Personalized medicine in thrombosis: back to the future.

Authors:  Srikanth Nagalla; Paul F Bray
Journal:  Blood       Date:  2016-02-04       Impact factor: 22.113

6.  Apolipoprotein E polymorphism is associated with lower extremity deep venous thrombosis: color-flow Doppler ultrasound evaluation.

Authors:  Shuangli Zhu; ZhiGang Wang; XiaoPing Wu; Yan Shu; DunXiang Lu
Journal:  Lipids Health Dis       Date:  2014-01-24       Impact factor: 3.876

7.  Next-Generation Sequencing and In Vitro Expression Study of ADAMTS13 Single Nucleotide Variants in Deep Vein Thrombosis.

Authors:  Maria Teresa Pagliari; Luca A Lotta; Hugoline G de Haan; Carla Valsecchi; Gloria Casoli; Silvia Pontiggia; Ida Martinelli; Serena M Passamonti; Frits R Rosendaal; Flora Peyvandi
Journal:  PLoS One       Date:  2016-11-01       Impact factor: 3.240

8.  Single Nucleotide Variant rs2232710 in the Protein Z-Dependent Protease Inhibitor (ZPI, SERPINA10) Gene Is Not Associated with Deep Vein Thrombosis.

Authors:  Marcin M Gorski; Luca A Lotta; Emanuela Pappalardo; Hugoline G de Haan; Serena M Passamonti; Astrid van Hylckama Vlieg; Ida Martinelli; Flora Peyvandi
Journal:  PLoS One       Date:  2016-03-16       Impact factor: 3.240

9.  Next generation sequencing to dissect the genetic architecture of KNG1 and F11 loci using factor XI levels as an intermediate phenotype of thrombosis.

Authors:  Laura Martin-Fernandez; Giovana Gavidia-Bovadilla; Irene Corrales; Helena Brunel; Lorena Ramírez; Sonia López; Juan Carlos Souto; Francisco Vidal; José Manuel Soria
Journal:  PLoS One       Date:  2017-04-26       Impact factor: 3.240

10.  Targeted sequencing to identify novel genetic risk factors for deep vein thrombosis: a study of 734 genes.

Authors:  H G de Haan; A van Hylckama Vlieg; L A Lotta; M M Gorski; P Bucciarelli; I Martinelli; T P Baglin; F Peyvandi; F R Rosendaal
Journal:  J Thromb Haemost       Date:  2018-10-16       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.